Novartis Access: Medicines to treat chronic diseases in lower-income countries

Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low and middle income countries.

Videos from this campaign

Content from this campaign

Awards, Ratings & Rankings

« Prix Hermès de l'innovation » for Novartis Access
Novartis Access is the 2016 winner of the "Prix Hermès de l'innovation" in the category “Improvement of the human condition”. Jürgen Brokatzky-Geiger, Head of Novartis Access, collected the award during the official ceremony in Paris on June 14.

Health & Healthcare

Perfecting Access Through Embedded Sustainability, Pooling Resources and Consolidating Expertise
Anthony Gitau is Country Head of Novartis Access and Familia Nawiri in Kenya. In his current role, Anthony Gitau is in charge of implementing and scaling up the two social business programs of Novartis in Kenya. These are meant to empower people living at the base of the pyramid to take control of their health and to give them access to quality affordable healthcare services and products. Anthony tells his story about his passion for working on affordable access programs on EFPIA Blog.

Health & Healthcare

Africa Has a New Health Challenge, and We Need a Plan to Fight It
While the headlines might focus on Ebola or yellow fever, Africa is slowly winning the fight against infectious diseases. They will remain a challenge for decades to come, but the real threat of the future is expected to come from elsewhere: non-communicable diseases (NCDs) like diabetes, cardiovascular disease and cancer. We must find creative new ways to tackle these health challenges, which will call for us to pool resources and expertise from all those involved in the delivery of healthcare.

Health & Healthcare

Novartis and Red Cross Partner to Tackle Chronic Diseases in Refugee Populations
Syrian refugees in Lebanon suffering from chronic diseases face difficulties accessing diagnosis, medicines and ongoing care. The International Committee of the Red Cross (ICRC) and Novartis are partnering to improve care and treatment for the most vulnerable population in Lebanon. The objective is to establish a blueprint for improving diagnosis, treatment and follow-up for refugees, as well as members of their Lebanese host families, who suffer from chronic diseases.

Sustainable Finance & Socially Responsible Investment

First Novartis Access Treatments Delivered to Kenya
We are pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer. The medicines are currently stored in the MEDS warehouse (Mission for Essential Drugs and Supplies) in Nairobi.

Health & Healthcare

Expanding Access to Affordable Treatments Against Chronic Diseases
On May 25, Novartis Access held its second stakeholder dialogue in conjunction with the 2016 World Health Assembly to share first learnings from the Kenya launch, and to continue the discussion on how to address the burden of noncommunicable diseases (NCDs) in lower-income countries. This event is part of the company’s public commitment to transparency and open dialogue with stakeholders as Novartis Access is rolled out.

Health & Healthcare

Kenya First Country to Launch ‘Novartis Access’, Expanding Affordable Treatment Options Against Chronic Diseases
Today, Novartis announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer. The Novartis portfolio is being offered to the Kenyan government, non-governmental organizations and other public-sector healthcare providers for USD 1 per treatment, per month.

Health & Healthcare

Novartis Launches ‘Novartis Access’, a Portfolio of Affordable Medicines to Treat Chronic Diseases in Lower-income Countries
Novartis today announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for USD 1 per treatment, per month.
Novartis logo

More from Novartis

  1. Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
    Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

  2. Novartis US Foundation
    Initiatives summarizing efforts from the Novartis US Foundation.

  3. Novartis COVID-19 Trials
    Novartis clinical trial efforts in COVID-19 R&D.

  4. Novartis US Foundation COVID-19 Response
    In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...

  5. Novartis – science based innovation for better patient outcomes
    Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

  6. Novartis Foundation Leprosy Elimination Initiative
    The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

  7. Novartis Access: Medicines to treat chronic diseases in lower-income countries
    Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

  8. The Novartis Malaria Initiative
    For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...